This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OMIC Singular Genomics Systems (OMIC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Singular Genomics Systems Stock (NASDAQ:OMIC) 30 days 90 days 365 days Advanced Chart Get OMIC alerts:Sign Up Key Stats Today's Range$20.01▼$20.0150-Day Range$20.01▼$20.0152-Week Range$5.34▼$23.41VolumeN/AAverage Volume54,671 shsMarket Capitalization$50.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California. Read More Receive OMIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address OMIC Stock News HeadlinesSingular Genomics Systems Inc (OMIC) - Investing.comJune 29, 2025 | investing.comSingular Genomics highlights G4X milestones at AGBTFebruary 24, 2025 | markets.businessinsider.comEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.July 30 at 2:00 AM | Stansberry Research (Ad)Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBTFebruary 24, 2025 | markets.businessinsider.comSingular Genomics announces closing of acquisition by Deerfield ManagmentFebruary 21, 2025 | markets.businessinsider.comSingular Genomics Shareholders Approve Merger AgreementFebruary 21, 2025 | investing.comSingular Genomics Announces Closing of Acquisition by Deerfield ManagementFebruary 21, 2025 | globenewswire.comSingular Genomics Systems IncFebruary 20, 2025 | morningstar.comMSee More Headlines OMIC Stock Analysis - Frequently Asked Questions How were Singular Genomics Systems' earnings last quarter? Singular Genomics Systems, Inc. (NASDAQ:OMIC) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($6.72) EPS for the quarter, topping the consensus estimate of ($8.05) by $1.33. The company earned $0.41 million during the quarter, compared to analysts' expectations of $0.74 million. Singular Genomics Systems had a negative net margin of 3,237.89% and a negative trailing twelve-month return on equity of 57.87%. When did Singular Genomics Systems' stock split? Singular Genomics Systems's stock reverse split on the morning of Wednesday, June 26th 2024.The 1-30 reverse split was announced on Wednesday, June 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Singular Genomics Systems IPO? Singular Genomics Systems (OMIC) raised $178 million in an IPO on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO. What other stocks do shareholders of Singular Genomics Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Singular Genomics Systems investors own include NVIDIA (NVDA), Tesla (TSLA), Albemarle (ALB), CrowdStrike (CRWD), Etsy (ETSY), Ford Motor (F) and Fluence Energy (FLNC). Company Calendar Last Earnings11/12/2024Today7/30/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:OMIC CIK1850906 Websingulargenomics.com Phone858-333-7830FaxN/AEmployees220Year FoundedN/AProfitability EPS (Trailing Twelve Months)($35.1096) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$94.82 million Net Margins-3,237.89% Pretax Margin-3,237.89% Return on Equity-57.87% Return on Assets-37.90% Debt Debt-to-Equity Ratio0.04 Current Ratio7.37 Quick Ratio6.67 Sales & Book Value Annual Sales$2.91 million Price / Sales17.47 Cash FlowN/A Price / Cash FlowN/A Book Value$73.25 per share Price / Book0.27Miscellaneous Outstanding Shares2,540,000Free Float1,974,000Market Cap$50.83 million OptionableNo Data Beta1.83 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:OMIC) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredSomething BIG is about to hit the stock marketMost investors won’t see it coming—but Weiss Ratings says a major market event is brewing. Their system jus...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Singular Genomics Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Singular Genomics Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.